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Abstract
Background: Though pharmacy claims data are commonly used to study medication adherence, there remains no
standard operational definition for adherence especially for patients on multiple medications. Even when studies
use the same terminology, the actual methods of calculating adherence can differ drastically. It is unclear whether
the use of different definitions results in different conclusions regarding adherence and associated outcomes. The
objective of our study was to compare adherence rates and associations with mortality using different operational
definitions of adherence, and using various methods of handling concurrent medication use.
Methods: We conducted a cohort study of patients aged ≥65 years from Manitoba, Canada, with incident
hypertension diagnosed in 2004 and followed to 2009. We calculated adherence rates to anti-hypertensive
medications using different operational definitions of medication adherence (including interval and prescription
based medication possession ratios [MPR] and proportion of days covered [PDC]). For those on concurrent
medications, we calculated adherence rates using the different methods of handling concurrent medication use, for
each definition. We used logistic regression to determine the association between adherence and mortality for
each operational definition.
Results: Among 2199 patients, 24.1% to 90.5% and 71.2% to 92.7% were considered adherent when using fixed
interval and prescription-based interval medication possession ratios [MPRi and MPRp] respectively, depending on
how concurrent medications were handled. Adherence was inversely associated with death, with the strongest
association for MPRp measures. This association was significant only when considering adherence to any anti-
hypertensive [aOR 0.70, 95% CI 0.51, 0.97], or when the mean of the class-specific MPRp’s [adjusted OR 0.71, 95% CI
0.53, 0.95] was used. No significant association existed when the highest or lowest class-specific MPRp was used as
the adherence estimate.
Conclusion: The range of adherence estimates varies widely depending on the operational definition used. Given
less variation in adherence rates and their stronger association against mortality, we recommend using prescription-
based MPR’s to define medication adherence.
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Background
Medication adherence is defined as the extent to which a
patient takes prescribed medications according to the dos-
age and frequency recommended by the provider [1, 2].
Non-adherence to prescribed medications is associated
with poor treatment outcomes, increased hospitalizations,
and increased cost to the health care system for chronic
diseases such as hypertension, diabetes, and heart failure
[3–5]. Despite the presence of a clinical definition of
medication adherence, there remains no standard oper-
ational definition for medication adherence in health re-
search, especially when using pharmacy claims data [6].
In the literature, there are a wide number of terms and
operational definitions used to assess medication adherence
(see Table 1 for a list of definitions used in the hypertension
literature). Even when studies use the same terms, the op-
erationalized or practical definition presented, the time
frame considered, and the method of calculating adherence
often differ. Most studies use the “medication possession
ratio” (MPR) [1, 7] or similar related adherence measures,
generally defined as the proportion of a time period where
a medication supply is available [1]. Variations in MPR cal-
culations stem from different denominators used, which
can either be a fixed time interval or a variable period be-
tween prescriptions. The former is termed “interval based
MPR” [MPRi] and the latter, “prescription based MPR”
[MPRp] [8]. MPR can be reported as a continuous or as a
dichotomized measure, where patients with an MPR above
a certain threshold are considered “adherent”. While the
level of optimal adherence may differ for different clinical
conditions, a threshold of 0.80 [1] is conventionally used.
Despite wide acceptance and usage of MPR, there re-
mains significant variation not only in its specific calcula-
tion as mentioned above, but also in methods of managing
multiple concurrent medications (“polytherapy”) to obtain
a single measure of adherence for each patient (see Table 2).
Methods of calculating an MPR estimate for patients on
polytherapy can consider either adherence to individual
drug classes or adherence overall to any medication. In
addition, a related measure to MPR termed Proportion of
Days Covered [PDC] is often preferred in polytherapy due
to its lower risk of overestimation [9]; PDC is defined as
the proportion of days in a fixed observation period where
at least one of multiple medications is available.
The many different operational definitions and
methods used to handle polytherapy may result in very
different adherence estimates and highly variable conclu-
sions [8], highlighting the need to harmonize operational
definitions of adherence used in health research. Our
study objective was to compare adherence rates using
the different operational definitions (MPRi, MPRp, and
PDC) and methods of handling concurrent medications,
and to determine the strengths of association between
medication adherence using these different operational
definitions with all-cause mortality in a population of
Canadians with newly diagnosed hypertension.
Methods
Sources of data
Administrative data extracted from hospital discharge ab-
stracts and physician claims were collected in Manitoba,
Canada from April 1, 1997 to March 31, 2009. We linked
this database with vital statistics for mortality data, the
health insurance registry for demographic data, and the
Manitoba Pharmacare prescription database for drug data.
Drug data from April 1, 2002 to March 31, 2009 were
used for this study. Given the universality of Manitoba
Pharmacare, this database contains dispensing records for
all outpatient prescription drug claims for all Manitoban
residents, with the exception of First Nations and Inuit
persons, inmates incarcerated in federal penitentiaries,
military personnel, RCMP, and veterans; these subgroups
are covered by the federal drug benefit plan [10]. Institu-
tional ethics board approval was obtained from the
University of Calgary Conjoint Health Research Ethics
Board. Manitoba Health granted access to the administra-
tive databases used in this study. Direct patient consent
was not obtained, as the data being analyzed were rou-
tinely collected administrative health data that had been
de-identified prior to receipt of data.
Study population
The 25 diagnosis fields in hospital discharge abstracts
and the 1 field in physician claims were searched for the
relevant International Classification of Diseases, Ninth
and Tenth Revisions (ICD-9 and ICD-10) codes for
hypertension (401.x-405.x, 110.x-115.x). The case defin-
ition for incident hypertension in the databases was one
hospitalization or two physician claims within 2 years
with a hypertension ICD code. We determined incidence
with a three-year washout period [11]. Index date of
diagnosis was the first date at which the case definition
was fulfilled. Patients without at least a single prescrip-
tion refill within one year after the first prescription fill
in any of the five antihypertensive medication classes of
interest (thiazide-type diuretics, beta blockers [BB], cal-
cium channel blockers [CCB], angiotensin converting
enzyme inhibitors or angiotensin receptor blockers
[ACEI/ARB], or a combination containing at least one of
the above classes; see Appendix 1), and patients who
died within one year of the first prescription fill were ex-
cluded to ensure that each operational definition could
be calculated for each patient. The study population in-
cluded a random sample of Manitoba residents aged ≥65
years with incident hypertension, with an index date of
diagnosis between April 1, 2004 and March 31, 2005.
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Sample size calculation
Using conservative assumptions, the target sample size,
assuming that the mortality rate of patients over the age
of 65 years old with hypertension who are non-adherent
to medications is 17% [12], to achieve a power of 80%, a
level of significance of 5%, and to detect a relative risk
ratio of mortality of 0.72 [13] for patients who are
adherent to medications compared with patients who
are non-adherent to medications, is 2124. To account
for the exclusion of approximately 30% of the entire
sample either because they have not had had a single fill
or refill of any anti-hypertensive medications in the en-
tire follow-up period, or die within the first year of diag-
nosis, 3000 patients with incident hypertension were
Table 2 Methods of handling use of multiple concurrent anti-hypertensive medications when measuring adherence in hypertension
literature
Measure Method of handling concurrent medications Method considers adherence to
any medication versus adherence
to each medication
CMG [24–26] Sum of the total number of gap days (days the
patient did not possess the medication) for each
anti-hypertensive medication divided by the sum
of the total number of days the patient was
prescribed each anti-hypertensive medication [24, 26]
Any
Calculate and report CMG for each
anti-hypertensive medication class [26]
Each
Calculate CMG for each anti-hypertensive
medication class, then take the mean
CMG for each patient [25]
Each
CSA [25] Calculate CSA for each anti-hypertensive
medication class, then take the mean CSA
for each patient [25]
Each
MPR [13, 25, 27–35] [39] Exclude patients not on monotherapy [28] N/A
Method of handling polytherapy not reported [33] N/A
Calculate and report for each class of
anti-hypertensive medication [27, 30]
Each
Take the single medication with the maximum
number of days supply over one year period
and use this single medication for the MPR
estimate for the patient [35]
Each
Calculate MPR for each anti-hypertensive
mediation class, then take the lowest MPR
(for the medication with lowest adherence)
as the MPR estimate for each patient [34, 39]
Each
Calculate MPR for each anti-hypertensive
medication class, then take the mean MPR
for each patient [25, 29, 32, 34]
Each
Include all days where at least one anti-hypertensive
medication was available in the numerator of the
ratio of number of days with medication to days
in study period [13]
Any
Calculate numerator for MPR by taking sum of all
days supply of all anti-hypertensive medications
prescribed as the numerator [40]
Any
Include only days where all anti-hypertensive
medications of interest were available [31]
Each
PDC [36, 37] Include all days where at least one anti-hypertensive
medication was available in the numerator of the
ratio of number of days with medication to days
in study period [36, 37]
Any
MedsIndex [33] Method of handling polytherapy not reported [33] N/A
Abbreviations: CMG Continuous multiple-interval gap, CSA Continuous single-interval medication availability, MPR Medication possession ratio, PDC proportion of
days covered, N/A Not applicable
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randomly selected for analysis. Random sampling was
performed using the probability proportional to size
method based on age, sex, and comorbidities.
Measures of medication adherence
We calculated MPR using the following 2 formulae
(interval-based and prescription-based MPR respect-
ively) for an observation period of 1 year:
MPRi ¼ Days supply of medication
365 days
; capped at 1
MPRp
¼ Days supply of medication excluding supply from last refill
Last refill date‐First refill date
; capped at 1
Medications within the same medication class
(Appendix 1) were considered interchangeable.
For patients on polytherapy in our study, we calculated
four different MPRi’s and MPRp’s: a) MPR considering ad-
herence to any antihypertensive, obtained by first sum-
ming the days supply of each anti-hypertensive
prescription in the numerator [9], then dividing by the de-
nominator as stated above; b) average of the MPR’s spe-
cific to each anti-hypertensive medication class [8, 14]; c)
calculating the MPR’s specific to each medication class,
then taking the highest of the class-specific MPR’s [15];
and d) calculating the MPR’s specific to each medication
class, then taking the lowest of the class-specific MPR’s
[16]. We termed these methods “sum MPR”, “mean
MPR”, “high MPR” and “low MPR” respectively. Of note,
for sum MPR, no medication class-specific MPRs are cal-
culated. The denominator used for sum MPRp is the last
refill date for any of the medication classes minus the first
refill date for any of the medication classes (even if this
medication class is not the same one used for the last refill
date). We also calculated PDC for each patient by dividing
the number of days where at least one medication was
available (each day is considered individually and is a bin-
ary measure) [9] by 365 days.
MPR’s and PDC’s were additionally dichotomized
using the standard threshold of 0.80. For patients on
anti-hypertensive therapy prior to the index date, adher-
ence measures were calculated from the first prescrip-
tion fill starting from 2002. If prescription refills were
obtained prior to exhaustion of the supply of the previ-
ous fill for the same medication class, the date of the re-
fill was prorated to start on the day after exhaustion of
the previous supply.
Mortality
The primary outcome measure was mortality from the
period 2005 to 2009 (a maximum of 5 years of follow-
up). Any patients moving out-of-province or reaching
the end of the observation period were censored.
Statistical analysis
Means and medians for continuous medication adher-
ence variables were reported. These variables were
also dichotomized, and Fisher’s exact test was used to
compare the proportion of adherent and non-
adherent patients who had died. We also stratified
this analysis by age, sex, income, and number of co-
morbidities. Multiple logistic regression models were
employed to model the odds of death for those who
are adherent to medications, compared to those who
were non-adherent to medications, using the different
operational definitions for adherence. The threshold
used to define adherence was an MPR or PDC ≥ 0.80.
Unadjusted and adjusted Cox proportional hazards re-
gressions were performed for each operational defin-
ition of adherence, to assess time to death. Given
their potential to confound the association between
medication adherence and mortality, we controlled for
demographic and comorbidity variables in our ad-
justed logistic regression and Cox proportional haz-
ards regression models; these variables included age,
sex, Charlson comorbidity index, income quintile, and
previous hospitalization for cardiovascular disease
within three years prior to the index date of hyper-
tension diagnosis. Data on health-related behaviours,
such as diet and activity levels, were not available
given the nature of data used in this study and thus
no adjustment for these variables were undertaken.
However, previous studies have shown weak correla-
tions and non-statistically significant associations
between health-related behaviours and medication
adherence [17–20]. Health-related behaviours are
therefore unlikely to be a significant confounder in
the associations between medication adherence and
mortality. All analyses were conducted using SAS
Version 9.4 (SAS Institute, Cary, NC).
Sensitivity analysis
Because there is no robust evidence base to suggest
that an MPR or PDC threshold of 0.80 used to clas-
sify those who are adherent versus non-adherent to
medications is optimal or superior to other thresh-
olds, we conducted sensitivity analysis, using various
other adherence thresholds. For this sensitivity ana-
lysis, adjusted logistic regression as described above
was also performed for thresholds of 0.70, 0.75, 0.85,




From a total of 5189 eligible patients aged 65 years
or older with incident hypertension diagnosed in the
2004 fiscal year, a random sample of 3000 patients
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were selected for analysis. Of this sample of 3000 pa-
tients, we excluded those with no prescription filled
for any anti-hypertensive in the entire follow-up
period (n = 652), those who died within one year of
their first anti-hypertensive prescription fill (n = 51),
and those without at least one medication refill
within one year of their first prescription fill (n = 98).
Our final cohort comprised of 2199 patients. The me-
dian and mean follow-up durations were 4.41 years
(interquartile range 4.11, 4.72) and 4.13 years (stand-
ard deviation 0.99) respectively.
Baseline characteristics can be found in Table 3. Over-
all, mean (SD) age was 75.2 (7.0) years, 45.4% were male,
12.2% had a previous hospitalization for cardiovascular
disease, 33.7% were new users of anti-hypertensives, and
64.7% were on monotherapy. Comparison of baseline
characteristics between non-adherent and adherent
groups depended on the adherence measure being used
(Table 3).
Adherence rates by operational definition
For patients on monotherapy (n = 1422), MPRi adher-
ence estimates (mean 0.83, SD 0.23) were similar
though consistently lower than the equivalent MPRp
estimates (mean 0.87, SD 0.19, see Table 4). The PDC
and MPRi methods gave identical adherence estimates
for those on monotherapy only. These findings were
consistent even with stratification by age, sex, income,
and comorbidities.
In polytherapy (n = 777), the range of adherence rates
varied widely, based on whether MPRi or MPRp was
used, and also depending on the method used to manage
polytherapy (Table 5). The lowest overall estimate of ad-
herence was with using the “low MPRi” method, or tak-
ing the lowest class-specific MPRi for each patient
(mean 0.47, SD 0.32). The highest overall estimate of ad-
herence was with using the “sum MPRi” method, or by
taking the sum of the days supply from each anti-
hypertensive medication class as the numerator in the
calculation of MPRi (mean 0.95, SD 0.13). “Mean MPRi”
(0.66, SD 0.23) and “high MPRi” (0.84, SD 0.21) resulted
in adherence estimates between these two extremes.
Similarly, when adherence measures were dichotomized,
the proportion of adherent users ranged from 24.1%
with “low MPRi” to 90.5% with “sum MPRi”. In contrast
to patients on monotherapy, PDC and MPRi (regardless
of the method used to handle polytherapy) do not give
the same adherence estimates for patients on
polytherapy.
The range of adherence was much narrower for
MPRp adherence estimates, with “low MPRp” giving
again the lowest adherence estimate (mean 0.84, SD
0.21) and “sum MPRp” giving the highest estimate
(mean 0.96, SD 0.12). The variation in the proportion
of adherent users was also much smaller using MPRp,
ranging from 71.2% with “low MPRp” to 92.7% with
“sum MPRp”. PDC gave a more conservative measure
compared to both sum MPRi and sum MPRp; 83.0%
of the sample was classified as adherent using PDC.
Even with stratification across age, sex, income, and
comorbidities, the same patterns could be seen where
MPRi’s gave much wider ranges of adherence esti-
mates compared with MPRp’s, with “low MPR” giving
the lowest estimates and “sum MPR” giving the high-
est estimates regardless of whether the prescription or
interval based MPR method was used.
Association between adherence and mortality
A total of 387 (17.6%) deaths occurred in the follow-
up period. Greater medication adherence was consist-
ently associated with lower odds of death, after risk
adjustment (see Table 6). Overall, the strength of as-
sociation was stronger for MPRp than for MPRi or
PDC (adjusted odds ratio [aOR] for “sum MPRp” was
0.70 [95% CI 0.51, 0.97] for “sum MPRi” aOR 0.78
[95% CI 0.58, 1.05], for PDC aOR 0.80 [95% CI 0.60,
1.07]). Of the numerous methods of handling concur-
rent medication use, “sum MPRp” and “mean MPRp”
had the strongest associations with mortality with
these being the only measures to reach statistical sig-
nificance (aOR 0.70 [95% CI 0.51, 0.97] and 0.71
[95% CI 0.53, 0.95] respectively).
Similarly, in monotherapy, the association between
medication adherence and mortality was stronger for
MPRp measures than for MPRi and PDC measures
based on point estimates, despite none reaching stat-
istical significance. In polytherapy patients, the same
inverse association could be seen between medication
adherence as measured by MPRp and death, with the
strongest associations seen again with “sum” and
“mean” MPRp, though again none reached statistical
significance.
Unadjusted and adjusted Cox proportional hazards re-
gression provided similar results to logistic regression.
However, testing of the proportional hazards assumption
indicated its violation. Kaplan-Meier survival curves re-
vealed a divergence of survival in adherent versus non-
adherent groups at approximately 3.5 to 4 years post
index date of hypertension diagnosis for MPRp defini-
tions (with a less prominent trend using MPRi and PDC
definitions).
Sensitivity analysis
Similar results were seen when adjusted logistic regres-
sion was performed using different adherence thresholds
for each of the operational definitions (Appendix 2).
Across all adherence thresholds, adherence estimates as
measured by MPRp were more strongly associated with
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mortality than as measured by MPRi. The MPRp defini-
tions that showed a statistically significant association
between adherence and mortality varied depending on
the adherence threshold used. Statistical significance for
this association was reached for mean MPRp when using
adherence thresholds of 0.70, 0.75, and 0.80; for sum
MPRp, the adherence thresholds were 0.80 and 0.85. For
low MPRp, statistical significance was reached when the
adherence threshold used was 0.70.
Discussion
In a cohort of 2199 patients with incident hyperten-
sion, we found that different definitions of medication
adherence resulted not only in different baseline char-
acteristics of “adherent” and “non-adherent” groups
but also vast differences in estimated adherence rates.
Similar to previous studies, adherence measures based
on a fixed observation period (MPRi and PDC) re-
sulted in lower adherence estimates compared with
variable observation periods based on prescription re-
fill dates (MPRp) [8, 21]. In addition, different
methods of calculating adherence for patients on
polytherapy provided very different estimates of ad-
herence [8]. For example, if only those with an MPRi
of ≥0.80 for each and every medication class were
considered adherent, only 24.1% would be classified
as being adherent. Conversely, if we considered those
with an overall MPRi of ≥0.80, when all medication
classes were grouped together, as adherent, over 90%
of the same sample population would be classified as
adherent. Therefore, given this wide variation in ad-
herence estimates and their implications on study
conclusions, it is imperative that future adherence
studies are transparent in providing information re-
garding: 1) specific operational definitions of adher-
ence used and the numerator and denominator used
in these calculations; and 2) the method used to man-
age polytherapy. Because adherence measure names
Table 4 Mean and median adherence rates, and proportion with adherence ≥0.80 for patients on monotherapy (n = 1422)
Range Mean (SD) Median (IQR) Proportion ≥0.80
Overall MPRi 0.04–1.00 0.83 (0.23) 0.95 (0.75, 0.99) 71.8%
MPRp 0.04–1.00 0.87 (0.19) 0.96 (0.82, 1.00) 76.7%
PDC 0.08–1.00 0.82 (0.23) 0.93 (0.72, 0.99) 67.9%
Age 65 to 74 years MPRi 0.08–1.00 0.82 (0.23) 0.93 (0.72, 0.99) 67.9%
MPRp 0.09–1.00 0.85 (0.21) 0.95 (0.78, 1.00) 73.6%
PDC 0.08–1.00 0.82 (0.23) 0.93 (0.72, 0.99) 67.9%
75 years and over MPRi 0.04–1.00 0.84 (0.22) 0.95 (0.77, 0.99) 73.4%
MPRp 0.04–1.00 0.87 (0.19) 0.96 (0.83, 1.00) 77.9%
PDC 0.04–1.00 0.84 (0.22) 0.95 (0.77, 0.99) 73.4%
Sex Male MPRi 0.04–1.00 0.82 (0.23) 0.94 (0.73, 0.99) 67.9%
MPRp 0.04–1.00 0.85 (0.21) 0.95 (0.80, 1.00) 73.6%
PDC 0.04–1.00 0.82 (0.23) 0.94 (0.73, 0.99) 67.9%
Female MPRi 0.10–1.00 0.84 (0.22) 0.96 (0.78, 0.99) 73.4%
MPRp 0.08–1.00 0.87 (0.19) 0.96 (0.82, 1.00) 77.9%
PDC 0.10–1.00 0.84 (0.22) 0.96 (0.78, 0.99) 73.4%
Income Lowest quintile MPRi 0.05–1.00 0.83 (0.24) 0.95 (0.77, 0.99) 73.1%
MPRp 0.04–1.00 0.87 (0.20) 0.96 (0.83, 1.00) 77.9%
PDC 0.05–1.00 0.83 (0.24) 0.95 (0.77, 0.99) 73.1%
Highest quintile MPRi 0.10–1.00 0.85 (0.20) 0.95 (0.74, 0.99) 71.7%
Charlson
comorbidities
0 or 1 comorbidities MPRi 0.04–1.00 0.84 (0.22) 0.95 (0.76, 0.99) 72.6%
MPRp 0.08–1.00 0.87 (0.19) 0.96 (0.82, 1.00) 77.2%
PDC 0.04–1.00 0.84 (0.22) 0.95 (0.76, 0.99) 72.6%
2+ comorbidities MPRi 0.05–1.00 0.79 (0.26) 0.92 (0.61, 1.00) 63.9%
MPRp 0.04–1.00 0.83 (0.23) 0.94 (0.77, 1.00) 71.5%
PDC 0.05–1.00 0.79 (0.26) 0.92 (0.61, 1.00) 63.9%
Abbreviations: SD standard deviation, IQR interquartile range, MPRi interval based medication possession ratio, MPRp prescription based medication possession
ratio, PDC proportion of days covered
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Table 5 Mean and median adherence rates and proportion with adherence ≥0.80 for patients on polytherapy (n = 777)
Range Mean (SD) Median (IQR) Proportion ≥0.80
Overall MPRi Low 0.01–1.00 0.47 (0.32) 0.41 (0.16, 0.77) 24.1%
High 0.15–1.00 0.84 (0.21) 0.93 (0.74, 0.99) 69.6%
Sum 0.25–1.00 0.95 (0.13) 1.00 (1.00, 1.00) 90.5%
Mean 0.11–1.00 0.66 (0.23) 0.64 (0.49, 0.87) 33.7%
MPRp Low 0.05–1.00 0.84 (0.21) 0.92 (0.77, 0.99) 71.2%
High 0.10–1.00 0.94 (0.13) 1.00 (0.94, 1.00) 89.5%
Sum 0.16–1.00 0.96 (0.12) 1.00 (1.00, 1.00) 92.7%
Mean 0.10–1.00 0.89 (0.15) 0.95 (0.84, 0.99) 81.0%
PDC 0.15–1.00 0.90 (0.18) 0.98 (0.90, 1.00) 83.0%
Age 65 to 74 years MPRi Low 0.01–1.00 0.50 (0.32) 0.48 (0.19, 0.82) 25.2%
High 0.16–1.00 0.85 (0.19) 0.92 (0.79, 0.99) 73.5%
Sum 0.33–1.00 0.97 (0.11) 1.00 (1.00, 1.00) 93.2%
Mean 0.11–1.00 0.67 (0.23) 0.69 (0.49, 0.88) 37.2%
MPRp Low 0.05–1.00 0.83 (0.22) 0.91 (0.78, 0.98) 71.8%
High 0.10–1.00 0.93 (0.15) 1.00 (0.94, 1.00) 89.7%
Sum 0.20–1.00 0.96 (0.12) 1.00 (1.00, 1.00) 92.7%
Mean 0.10–1.00 0.88 (0.17) 0.94 (0.84, 0.99) 82.5%
PDC 0.16–1.00 0.91 (0.16) 0.98 (0.91, 1.00) 85.9%
75 years and over MPRi Low 0.01–1.00 0.46 (0.33) 0.39 (0.16, 0.76) 23.6%
High 0.15–1.00 0.83 (0.21) 0.94 (0.74, 0.99) 68.0%
Sum 0.25–1.00 0.95 (0.14) 1.00 (1.00, 1.00) 89.3%
Mean 0.11–1.00 0.65 (0.23) 0.63 (0.48, 0.87) 32.2%
MPRp Low 0.08–1.00 0.84 (0.21) 0.93 (0.77, 0.99) 70.9%
High 0.20–1.00 0.94 (0.12) 1.00 (0.94, 1.00) 89.4%
Sum 0.16–1.00 0.96 (0.11) 1.00 (1.00, 1.00) 92.6%
Mean 0.15–1.00 0.89 (0.15) 0.96 (0.85, 0.99) 80.3%
PDC 0.15–1.00 0.89 (0.19) 0.99 (0.88, 1.00) 81.8%
Sex Male MPRi Low 0.01–1.00 0.50 (0.33) 0.44 (0.16, 0.82) 26.2%
High 0.15–1.00 0.83 (0.22) 0.93 (0.74, 0.99) 69.2%
Sum 0.25–1.00 0.94 (0.15) 1.00 (1.00, 1.00) 89.1%
Mean 0.11–1.00 0.66 (0.24) 0.67 (0.48, 0.88) 36.6%
MPRp Low 0.05–1.00 0.83 (0.22) 0.92 (0.78, 0.98) 70.5%
High 0.18–1.00 0.93 (0.14) 0.99 (0.93, 1.0) 90.8%
Sum 0.16–1.00 0.96 (0.13) 1.00 (1.00, 1.00) 91.9%
Mean 0.15–1.00 0.88 (0.16) 0.95 (0.84, 0.99) 80.9%
PDC 0.15–1.00 0.88 (0.20) 0.98 (0.85, 1.00) 80.4%
Female MPRi Low 0.01–1.00 0.45 (0.32) 0.38 (0.16, 0.74) 22.3%
High 0.16–1.00 0.84 (0.19) 0.94 (0.75, 0.99) 70.0%
Sum 0.33–1.00 0.96 (0.12) 1.00 (1.00, 1.00) 91.6%
Mean 0.11–1.00 0.65 (0.22) 0.63 (0.49, 0.86) 31.4%
MPRp Low 0.10–1.00 0.84 (0.20) 0.93 (0.77, 0.99) 71.7%
High 0.10–1.00 0.94 (0.13) 1.00 (0.95, 1.00) 88.5%
Sum 0.20–1.00 0.97 (0.10) 1.00 (1.00, 1.00) 93.3%
Mean 0.10–1.00 0.89 (0.15) 0.95 (0.85, 0.99) 81.0%
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and corresponding calculations are inconsistent across
studies [7], we note that adherence measure terms
alone are inadequate in describing the differences in
calculations.
Adjusted logistic regression revealed that regardless of
the operational definition used for medication adher-
ence, there was a non-statistically significant trend
between adherence to anti-hypertensive medications and
lower risk of death. The strength of association was
greater in prescription-based measures compared with
interval-based measures. However, both methods are
not without their faults. While prescription-based
measures likely overestimate adherence by not ac-
counting for patients who inappropriately discontinue
Table 5 Mean and median adherence rates and proportion with adherence ≥0.80 for patients on polytherapy (n = 777) (Continued)
PDC 0.16–1.00 0.91 (0.16) 0.99 (0.91, 1.00) 85.1%
Income Lowest quintile MPRi Low 0.01–1.00 0.47 (0.31) 0.42 (0.16, 0.75) 20.1%
High 0.16–1.00 0.83 (0.21) 0.93 (0.74, 0.99) 66.9%
Sum 0.33–1.00 0.95 (0.14) 1.00 (1.00, 1.00) 90.7%
Mean 0. 11–1.00 0.65 (0.23) 0.63 (0.46, 0.86) 35.3%
MPRp Low 0.10–1.00 0.79 (0.24) 0.89 (0.68, 0.99) 61.6%
High 0.10–1.00 0.92 (0.16) 1.00 (0.91, 1.00) 85.5%
Sum 0.16–1.00 0.94 (0.15) 1.00 (1.00, 1.00) 88.5%
Mean 0.10–1.00 0.86 (0.18) 0.92 (0.80, 0.99) 74.6%
PDC 0.16–1.00 0.88 (0.19) 0.98 (0.84, 1.00) 79.1%
Highest quintile MPRi Low 0.01–1.00 0.47 (0.32) 0.40 (0.16, 0.79) 24.6%
High 0.19–1.00 0.83 (0.20) 0.93 (0.69, 0.99) 67.5%
Sum 0.36–1.00 0.95 (0.12) 1.00 (1.00, 1.00) 90.5%
Mean 0. 12–1.00 0.65 (0.23) 0.63 (0.49, 0.88) 31.8%
MPRp Low 0.14–1.00 0.87 (0.17) 0.94 (0.81, 0.99) 77.6%
High 0.42–1.00 0.94 (0.11) 1.00 (0.95, 1.00) 92.0%
Sum 0.35–1.00 0.96 (0.11) 1.00 (1.00, 1.00) 92.9%
Mean 0.31–1.00 0.91 (0.13) 0.96 (0.87, 0.99) 86.4%
PDC 0.19–1.00 0.91 (0.17) 0.99 (0.92, 0.99) 86.5%
Charlson
comorbidities
0 or 1 comorbidities MPRi Low 0.01–1.00 0.46 (0.32) 0.41 (0.16, 0.76) 23.1%
High 0.15–1.00 0.83 (0.21) 0.93 (0.74, 0.99) 69.1%
Sum 0.25–1.00 0.95 (0.14) 1.00 (1.00, 1.00) 90.2%
Mean 0.11–1.00 0.65 (0.23) 0.63 (0.48, 0.87) 32.3%
MPRp Low 0.05–1.00 0.83 (0.21) 0.92 (0.77, 0.99) 71.1%
High 0.10–1.00 0.94 (0.13) 1.00 (0.94, 1.00) 89.5%
Sum 0.16–1.00 0.96 (0.12) 1.00 (1.00, 1.00) 92.7%
Mean 0.10–1.00 0.89 (0.16) 0.95 (0.84, 0.99) 80.5%
PDC 0.15–1.00 0.90 (0.18) 0.98 (0.90, 1.00) 83.1%
2+ comorbidities MPRi Low 0.05–1.00 0.54 (0.34) 0.57 (0.16, 0.85) 33.3%
High 0.25–1.00 0.86 (0.19) 0.96 (0.80, 1.00) 74.7%
Sum 0.41–1.00 0.97 (0.10) 1.00 (1.00, 1.00) 93.3%
Mean 0.11–1.00 0.71 (0.24) 0.76 (0.51, 0.92) 46.7%
MPRp Low 0.08–1.00 0.85 (0.19) 0.93 (0.75, 0.99) 72.0%
High 0.48–1.00 0.94 (0.12) 1.00 (0.96, 1.00) 89.3%
Sum 0.53–1.00 0.97 (0.09) 1.00 (1.00, 1.00) 92.0%
Mean 0.36–1.00 0.90 (0.13) 0.95 (0.85, 0.99) 85.3%
PDC 0.25–1.00 0.91 (0.15) 0.99 (0.88, 1.00) 82.7%
Abbreviations: SD standard deviation, IQR interquartile range, MPRi interval based medication possession ratio, MPRp prescription based medication possession
ratio, PDC proportion of days covered
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their medications [22], interval-based measures likely
underestimate adherence, by interpreting medication
switches as non-adherence.
Our sensitivity analysis revealed that the oper-
ational definitions that demonstrate the strongest and
most significant associations between adherence and
mortality vary depending upon the adherence thresh-
old used. When using low MPRp, adherence above
the threshold of 0.70 is significantly associated with
lower risk of mortality; this significance is lost when
higher thresholds are used. For mean MPRp mea-
sures, adherence using the thresholds of 0.70 to 0.80
is associated with reduced risk of death, but not
when using higher thresholds of 0.85 or 0.90. For
sum MPRp, adherence above the threshold of 0.80
and 0.85 is associated with reduced risk of death.
Therefore, the optimal adherence threshold may dif-
fer based on the method used to handle polytherapy.
When using stringent measures of adherence (such
as when adherence is measured based on the medica-
tion with lowest adherence in the case of low
MPRp), a lower adherence threshold such as 0.70
may be preferred. In contrast, when using a more
liberal measure of adherence (such as considering a
patient adherent even if he or she adheres to only
one of numerous medications, such as in the case of
sum MPRp), a higher adherence threshold such as
0.80 or 0.85 may be preferred.
For the standard adherence threshold of 0.80, the
adherence-mortality association reached statistical
significance only when using mean and sum
prescription-based MPR measures. These measures
likely reflect “overall” adherence to a patient’s full
regimen of anti-hypertensive medications. Being ad-
herent to only one medication and non-adherent to
others (that is, taking into account only highest
MPR) is not significantly associated with reduced risk
of death, as it may not reflect global adherence to all
medications. In contrast, adherence based on “low
MPR” (that is, all medication classes must have ad-
herence ≥0.80) is likely too stringent a criterion, and
its high specificity would result in many patients be-
ing considered non-adherent. The mean and sum
MPRp are likely a balance between these two ex-
tremes, where non-adherence to at least one medica-
tion class in a regimen can profoundly affect these
adherence estimates. Our study suggests that mean
and sum MPRp are the preferred operational mea-
sures of adherence, when using the adherence thresh-
old of 0.80, given their significant association with
mortality.
Certain limitations in our study deserve consideration.
First, to allow calculation of medication adherence over
a one-year observation period, we excluded patients who
died or did not have at least one prescription refill
within one year of their first prescription fill. We have
therefore likely excluded those who are sickest and most
dependent on chronic medication therapy, and those
who are most non-adherent. As a result, adherence is
likely overestimated and the association between adher-
ence and mortality weakened. Second, a maximum of
five years of follow-up may be insufficiently long to as-
sess association between adherence and mortality. This
concern is supported by Kaplan Meier survival curves
showing divergence for the non-adherent and adherent
groups beginning only at 3.5 to 4 years from index date
of diagnosis. Third, it is possible that the older age of
the sample population could have confounded the asso-
ciation between medication adherence and mortality. A
Cochrane systematic review showed that in the elderly
Table 6 Adjusted logistic regression modeling the odds ratio of
death, for patients who are adherent versus non-adherent to
anti-hypertensive medication
Adjusted ORb 95% CI P value
Overall MPRi Low 0.96 (0.74, 1.23) 0.743
High 0.90 (0.68, 1.19) 0.475
Sum 0.78 (0.58, 1.05) 0.104
Mean 0.88 (0.68, 1.13) 0.321
MPRp Low 0.79 (0.59, 1.05) 0.098
High 0.76 (0.56, 1.05) 0.094
Sum 0.70 (0.51, 0.97) 0.029
Mean 0.71 (0.53, 0.95) 0.021
PDC 0.80 (0.60, 1.07) 0.130
Monotherapy MPRi 0.80 (0.40, 1.57) 0.510
MPRp 0.74 (0.33, 1.66) 0.461
PDC 0.80 (0.40, 1.57) 0.510
Polytherapy MPRi Low 1.06 (0.64, 1.73) 0.832
High 1.15 (0.71, 1.85) 0.578
Sum 0.74 (0.37, 1.49) 0.400
Mean 0.83 (0.53, 1.31) 0.426
MPRp Low 0.84 (0.53, 1.33) 0.455
High 0.99 (0.50, 1.97) 0.975
Sum 0.65 (0.31, 1.36) 0.251
Mean 0.66 (0.40, 1.10) 0.112
PDC 0.80 (0.46, 1.38) 0.424
b Adjusted for age, sex, Charlson comorbidity index, income quintile, and
previous hospitalization for cardiovascular disease
Where “Low” = adherence estimate for the single medication class with the
lowest adherence; “High” = adherence estimate for the single medication class
with the highest adherence; “Sum” = adherence to any medication class
(where days supply for each medication class summed as the numerator);
“Mean” =mean adherence to each medication class
Abbreviations: OR odds ratio, CI confidence interval, MPRi interval based
medication possession ratio, MPRp prescription based medication possession
ratio, PDC proportion of days covered
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aged 80 years or older, anti-hypertensive therapy did not
reduce total mortality, though it did reduce cardiovascu-
lar mortality and morbidity [23]. Because 25% of our
sample population is aged 80 years or older, in whom
there may not be mortality benefit of anti-hypertensive
therapy, the overall associations between anti-
hypertensive adherence and mortality may have been
weakened by this subgroup. Fourth, because we did not
directly compare the different operational definitions of
adherence, we cannot state the superiority of one defin-
ition over another and therefore cannot recommend a
single standardized operational definition for adherence.
Rather, our findings suggest that different operational
definitions of adherence result in very different estimates
of adherence, and certain definitions are associated with
long-term outcomes in patients with hypertension, while
others are not. Lastly, we used adherence thresholds of
0.80 and a one-year observation period due to its wide
usage throughout the literature, despite limited evidence
to support these parameters. However, our sensitivity
analysis shows similar results and conclusions when
using varying adherence thresholds. We recommend
confirmation of our findings in a separate large cohort
of patients with hypertension, to ensure the validity and
generalizability of our conclusions.
Conclusion
This study is an important contribution to the litera-
ture, by providing a better understanding of com-
monly used medication adherence definitions and
their association with outcomes. We recommend the
use of prescription-based denominators when calculat-
ing medication possession ratios and related measures
given their narrower range of estimates and stronger
associations with long-term outcomes. In patients
using concurrent medications, we recommend using
the methods of handling polytherapy that are most
strongly associated with mortality. For a standard ad-
herence threshold of 0.80, these include the mean
medication possession ratio (measured as an average
of individual class-specific MPRs) and “sum” medica-
tion possession ratio (measured as adherence to any
medications in the relevant medication classes). We
have shown clearly that different operational defini-
tions of medication adherence and different methods
of handling polytherapy can result in a wide range of
adherence estimates and therefore conclusions
reached about adherence, highlighting the need to
harmonize these definitions. Given these implications,
it is of utmost importance that future adherence stud-
ies using pharmacy claims data carefully select and
describe the medication adherence definitions used,
especially for patients using multiple concurrent
medications.
Appendix 1
Table 7 Antihypertensive medication classes
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Appendix 2
Abbreviations
ACEI: Angiotensin converting enzyme inhibitor; aOR: Adjusted odds ratio;
ARB: Angiotensin receptor blocker; BB: Beta blocker; CCB: Calcium channel
blocker; CI: Confidence interval; ICD-10: International Classification of
Diseases, Tenth Revision; ICD-9: International Classification of Diseases, Ninth
Revision; MPR: Medication possession ratio; MPRi: Interval based medication
possession ratio; MPRp: Prescription based medication possession ratio;
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Table 8 Sensitivity analysis for odds ratios modeling death, for
patients who are adherent versus non-adherent to anti-
hypertensive medication, using different thresholds to define
adherence
Adjusted ORa 95% CI P value
Adherence >0.65 MPRi Low 0.96 (0.74, 1.26) 0.787
High 0.91 (0.65, 1.26) 0.560
Sum 0.89 (0.62, 1.27) 0.509
Mean 0.99 (0.75, 1.31) 0.940
MPRp Low 0.74 (0.52, 1.06) 0.101
High 0.81 (0.53, 1.23) 0.317
Sum 0.80 (0.52, 1.22) 0.294
Mean 0.78 (0.53, 1.16) 0.222
PDC 0.84 (0.60, 1.14) 0.323
Adherence >0.70 MPRi Low 0.92 (0.71, 1.19) 0.514
High 0.87 (0.64, 1.19) 0.385
Sum 0.78 (0.56, 1.09) 0.151
Mean 0.88 (0.67, 1.14) 0.324
MPRp Low 0.71 (0.51, 0.98) 0.036
High 0.71 (0.49, 1.02) 0.063
Sum 0.69 (0.48, 1.00) 0.052
Mean 0.64 (0.45, 0.90) 0.011
PDC 0.77 (0.56, 1.07) 0.117
Adherence >0.75 MPRi Low 0.96 (0.75, 1.24) 0.767
High 0.91 (0.68, 1.21) 0.515
Sum 0.81 (0.59, 1.11) 0.186
Mean 0.88 (0.68, 1.14) 0.322
MPRp Low 0.74 (0.55, 1.00) 0.053
High 0.77 (0.54, 1.08) 0.132
Sum 0.71 (0.50, 1.00) 0.052
Mean 0.70 (0.51, 0.97) 0.030
PDC 0.82 (0.61, 1.11) 0.203
Adherence >0.80 MPRi Low 0.96 (0.74, 1.23) 0.743
High 0.90 (0.68, 1.19) 0.475
Sum 0.78 (0.58, 1.05) 0.104
Mean 0.88 (0.68, 1.13) 0.321
MPRp Low 0.79 (0.59, 1.05) 0.098
High 0.76 (0.56, 1.05) 0.094
Sum 0.70 (0.51, 0.97) 0.029
Mean 0.71 (0.53, 0.95) 0.021
PDC 0.80 (0.60, 1.07) 0.130
Adherence >0.85 MPRi Low 0.89 (0.69, 1.15) 0.367
High 0.83 (0.64, 1.08) 0.175
Sum 0.75 (0.57, 0.99) 0.044
Table 8 Sensitivity analysis for odds ratios modeling death, for
patients who are adherent versus non-adherent to anti-
hypertensive medication, using different thresholds to define
adherence (Continued)
Mean 0.88 (0.69, 1.13) 0.329
MPRp Low 0.80 (0.61, 1.05) 0.103
High 0.80 (0.59, 1.07) 0.136
Sum 0.70 (0.52, 0.94) 0.018
Mean 0.80 (0.61, 1.06) 0.120
PDC 0.79 (0.60, 1.04) 0.095
Adherence >0.90 MPRi Low 0.95 (0.74, 1.23) 0.713
High 0.92 (0.71, 1.18) 0.500
Sum 0.85 (0.65, 1.12) 0.244
Mean 0.93 (0.72, 1.20) 0.589
MPRp Low 0.83 (0.64, 1.07) 0.156
High 0.89 (0.68, 1.18) 0.427
Sum 0.79 (0.59, 1.04) 0.094
Mean 0.86 (0.66, 1.11) 0.250
PDC 0.88 (0.67, 1.14) 0.332
a Adjusted for age, sex, Charlson comorbidity index, income quintile, and
previous hospitalization for cardiovascular disease
Where “Low” = adherence estimate for the single medication class with the
lowest adherence; “High” = adherence estimate for the single medication class
with the highest adherence; “Sum” = adherence to any medication class
(where days supply for each medication class summed as the numerator);
“Mean” =mean adherence to each medication class
Abbreviations: OR odds ratio, CI confidence interval, MPRi interval based
medication possession ratio, MPRp prescription based medication possession
ratio, PDC proportion of days covered
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